News

Jude Savarraj, PhD, discusses the accurate performance of his team’s machine learning models in predicting subarachnoid hemorrhage outcomes.

The director of the Massachusetts General Hospital ALS Care Center discussed the origins of ‘The Data is Here’ campaign and the reason to launch it now.

Clinically relevant scores of 32 and 44 on the Fugl-Meyer Motor Score were documented in 2 patients who received NSI-566.

Neurology News Network for the week ending January 30, 2021.

The study also found that patients with PD that used telehealth for mental health services were less likely to prefer telehealth over in-office visits.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

The investigational agent developed by Biogen and Eisai is now expected to receive regulatory review by June 7, 2021.

The observed increase in QOLIE-31 scores for patients with refractory disease was driven by increases on the energy-fatigue domain.

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

The primary investigator of the phase 4 RESPOND study discussed the role that postmarketing studies can play in assessing treatments for SMA.

Valproic acid’s efficacy as a monotherapy is complicated by its previously demonstrated unsuitability for pregnant women.

Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.

Brian Frederick, PhD, discusses how the short life expectancy after diagnosis leads many patients with ALS to lose their lives before receiving disability benefits.

Biohaven executives remain optimistic about the slight but insignificant improvement observed in those with mild AD.

The clinical fellow at Massachusetts General Hospital gives his call to action on how what needs to change to improve EEG education among residency programs.

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

Creative Medical Technology’s ImmCelz contrasts other stem cell-based approaches by utilizing stem cells outside of the body to reprogram the patient’s own immune cells.

Researchers hope that R-loop modulation may hold potential in the future treatment of ALS.

The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.

If approved, adaptive DBS could be added to Medtronic’s Percept device, which was approved in June 2020.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.

Researchers developed and trained a random forest classifier that resulted in high precision and accuracy as a screening tool for those with mild cognitive impairment.

Researchers sought to redefine dichotomous classifications of MS and identified meaningful classifications.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided background on a recently completed study correlating sleep and cognitive decline.

Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervates muscles throughout the body.

Brian Wainger, MD, PhD, assistant professor of neurology and anesthesiology, Harvard Medical School, discussed the recently published phase 2 trial a repurposed epilepsy drug in patients with ALS.